Fulgent Genetics, Inc. $FLGT Stake Raised by UBS Group AG

UBS Group AG boosted its holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 288.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 83,559 shares of the company’s stock after purchasing an additional 62,070 shares during the quarter. UBS Group AG’s holdings in Fulgent Genetics were worth $2,195,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of FLGT. Farther Finance Advisors LLC raised its holdings in Fulgent Genetics by 69.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after buying an additional 548 shares during the period. Raymond James Financial Inc. acquired a new stake in Fulgent Genetics during the 2nd quarter worth about $49,000. Flagship Harbor Advisors LLC acquired a new stake in Fulgent Genetics during the 4th quarter worth about $56,000. Quantbot Technologies LP acquired a new stake in Fulgent Genetics during the 3rd quarter worth about $61,000. Finally, Unison Advisors LLC acquired a new stake in Fulgent Genetics during the 4th quarter worth about $230,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Price Performance

NASDAQ:FLGT opened at $17.90 on Thursday. Fulgent Genetics, Inc. has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The stock’s 50-day moving average is $15.99 and its two-hundred day moving average is $22.00. The stock has a market cap of $508.36 million, a PE ratio of -7.49 and a beta of 0.88.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.The company had revenue of $83.34 million for the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, equities research analysts anticipate that Fulgent Genetics, Inc. will post -2.81 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on FLGT. Piper Sandler restated a “neutral” rating and set a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Finally, Wall Street Zen downgraded Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $27.00.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.